Skip Navigation

European Heart Journal 2001 22(19):1772-1784; doi:10.1053/euhj.2000.2557
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cowburn, P.J.
Right arrow Articles by Cleland, J.G.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cowburn, P.J.
Right arrow Articles by Cleland, J.G.F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Review

Endothelin antagonists for chronic heart failure: do they have a role?

P.J. Cowburna,f1 and J.G.F. Clelandb

a Southampton General Hospital, Southampton, Hants, U.K.
b Department of Cardiology, University of Hull, Castle Hill Hospital, Kingston upon Hull, U.K.

revised November 28, 2000; accepted November 29, 2000

f1 Correspondence: Dr Peter J. Cowburn, Wessex Cardiothoracic Centre, E level, East Wing, Mailpoint 46, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, U.K.

References

  1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of the arterial smooth muscle by acetylcholine. Nature. 1980;299:373–376
  2. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524–526[CrossRef][Medline]
  3. Hickey KA, Rubanyi G, Paul RJ, Highsmith RF. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol. 1985;248:C550–556[Web of Science][Medline]
  4. Yanagisawa M, Kurihara H, Kimura S. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415[CrossRef][Medline]
  5. Haynes WG, Webb DJ. The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci. 1993;84:485–500[Web of Science][Medline]
  6. Levin ER. Endothelins. N Engl J Med. 1995;333:356–363[Free Full Text]
  7. Francis GS, Benedict C, Johnstone DE. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation. 1990;82:1724–1729[Abstract/Free Full Text]
  8. Bayliss J, Norell M, Canepa Anson R. Untreated heart failure: Clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17–22[Abstract/Free Full Text]
  9. Cleland JGF, Cowburn PJ, Morgan K. Neuroendocrine activation after myocardial infarction: causes and consequences. Heart. 1996;76:53–59[Web of Science][Medline]
  10. Cowburn PJ, Cleland JGF, Coats AJS, Komajda M. Risk stratification in chronic heart failure. Eur Heart J. 1998;19:696–710[Free Full Text]
  11. N Engl J Med. 1987;316:1429–1435[Abstract]
  12. N Engl J Med. 1991;325:293–302[Abstract]
  13. Dickstein K, Chang P, Willenheimer R. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 1995;26:438–445[Abstract]
  14. Pitt B, Segal R, Martinez FA. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747–752[CrossRef][Web of Science][Medline]
  15. Packer M, Bristow MR, Cohn JN. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349–1355[Abstract/Free Full Text]
  16. Lancet. 1999;353:9–13[CrossRef][Web of Science][Medline]
  17. Lancet. 1999;353:2001–2007[CrossRef][Web of Science][Medline]
  18. Remme WJ, Cleland JGF, Dargie H. European Society of Cardiology: Guidelines for the management of heart failure. Eur Heart J. 1997;18:736–753[Free Full Text]
  19. Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 1999;83:1A–38A[CrossRef][Web of Science][Medline]
  20. Pitt B, Zannad F, Remme WJ. The effect of spironolactone on morbidity and mortality in patients with severe chronic heart failure. N Engl J Med. 1999;341:709–717[Abstract/Free Full Text]
  21. Cleland JGF, McGowan J, Clark A. Successes and failures of current treatment of heart failure. Lancet. 1998;352:s19–28
  22. Cleland JGF, McGowan J, Clark A. The evidence for beta blockers in heart failure. BMJ. 1999;318:824–825[Free Full Text]
  23. Hiroe M, Hirata Y, Fujita N. Plasma endothelin levels in idiopathic dilated cardiomyopathy. Am J Cardiol. 1991;68:1114–1115[CrossRef][Web of Science][Medline]
  24. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation. 1992;85:1374–1379[Abstract/Free Full Text]
  25. Cacoub P, Dorent R, Nataf P. Plasma endothelin and pulmonary pressures in patients with congestive heart failure. Am Heart J. 1993;126:1484–1488[CrossRef][Web of Science][Medline]
  26. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504–509[Abstract/Free Full Text]
  27. Wei CM, Lerman A, Rodeheffer RJ. Endothelin in human congestive heart failure. Circulation. 1994;89:1580–1586[Abstract/Free Full Text]
  28. Pousset F, Isnard R, Lechat P. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J. 1997;18:254–258[Abstract/Free Full Text]
  29. Love MP, McMurray JJV. Endothelin in chronic heart failure: Current position and future prospects. Cardiovasc Res. 1996;31:665–674[CrossRef][Web of Science][Medline]
  30. Benigni A, Remuzzi G. Endothelin antagonists. Lancet. 1999;353:133–138[CrossRef][Web of Science][Medline]
  31. Inoue A, Yanagisawa M, Kimura S. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA. 1989;86:2863–2867[Abstract/Free Full Text]
  32. Suzuki N, Matsumoto H, Kitada C, Masaki T, Fujino M. A sensitive sandwich-enzyme immunoassay for human endothelin. J Immunol Methods. 1989;118:245–250[CrossRef][Web of Science][Medline]
  33. Howard PG, Plumpton C, Davenport AP. Anatomical localisation and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens. 1992;10:1379–1386[CrossRef][Web of Science][Medline]
  34. Xu D, Emoto N, Giaid A. ECE-1: a membrane bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 1994;78:473–485[CrossRef][Web of Science][Medline]
  35. Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane bound, phosphoramidon sensitive metalloprotease with acidic pH optimum. J Biol Chem. 1995;270:15262–15268[Abstract/Free Full Text]
  36. Schweizer A, Valdenaire O, Nelbock P. Human endothelin-converting enzyme (ECE-1): three isoforms with three distinct subcellular locations. Biochem J. 1997;328:871–877[Web of Science][Medline]
  37. Valdenaire O, LepailleurEnouf D, Edigy G. A fourth isoenzyme of endothelin-converting enzyme (ECE-1a) is generated from an additional promoter-molecular cloning and characterisation. Eur J Biochemistry. 1999;264:341–349[Web of Science][Medline]
  38. Mumford RA, Pierzchala PA, Strauss AW, Zimmerman M. Purification of a membrane bound metalloendopeptidase from porcine kidney that degrades peptide hormones. Proc Natl Acad Sci USA. 1981;78:6623–6627[Abstract/Free Full Text]
  39. Vijayaraghavan J, Scicli AG, Carretero OA. The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase). J Biol Chem. 1990;265:14150–14155[Abstract/Free Full Text]
  40. Ferro CJ, Spratt JC, Haynes WG, Webb DJ. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation. 1998;97:2323–2330[Abstract/Free Full Text]
  41. Murphy LJ, Corder M, Mallet AI, Turner AJ. Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and C-terminal fragment from big endothelin-1. Br J Pharmacol. 1994;113:137–142[Web of Science][Medline]
  42. Arai H, Hori S, Arimori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348:730–732[CrossRef][Medline]
  43. Sakurai T, Yanagisawa M, Takuwa Y. Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor. Nature. 1990;348:732–735[CrossRef][Medline]
  44. Hosoda K, Nakao K, Hiroshi A. Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett. 1991;287:23–26[CrossRef][Web of Science][Medline]
  45. Williams DL, Jones KL, Colton CD, Nutt RF. Identification of high affinity endothelin-1 receptor sub-types in human tissues. Biochem Biophys Res Comm. 1991;180:475–480[CrossRef][Web of Science][Medline]
  46. Ogawa Y, Nakao K, Arai H. Molecular cloning of a non-isopeptide-selective human endothelin receptor. Biochem Biophys Res Comm. 1991;178:248–255[CrossRef][Web of Science][Medline]
  47. Davenport AP, O'Reilly G, Molenaar P. Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: Evidence for expression of ET(B) receptors in human vascular smooth muscle. J Cardiovasc Pharmacol. 1993;22:S22–25
  48. De Nucci G, Thomas R, D'Orleans-Juste P. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA. 1988;85:9797–9800[Abstract/Free Full Text]
  49. Clozel M, Gray GA, Breu V, Loffler B, Osrewalder R. The endothelin ETBreceptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Comm. 1992;186:867–873[CrossRef][Web of Science][Medline]
  50. Haynes WG, Webb DJ. Endothelium-dependent modulation of responses to endothelin-1 in human veins. Clin Sci. 1993;84:427–433[Web of Science][Medline]
  51. Seo B, Oemar BS, Siebenmann R, Von Segesser L, Luscher TF. Both ET(A) and ET(B) receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 1994;89:1203–1208[Abstract/Free Full Text]
  52. Haynes WG, Strachan FE, Webb DJ. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation. 1995;92:357–363[Abstract/Free Full Text]
  53. Karne S, Jayawickreme CK, Lerner MR. Cloning and characterisation of an endothelin-3 specific receptor (ETC) receptor from Xenopus laevis dermal melanophores. J Biol Chem. 1993;268:19126–19133[Abstract/Free Full Text]
  54. Lecoin L, Sakurai T, Ngo NT. Cloning and characterisation of a novel endothelin receptor subtype in the avian class. Proc Natl Acad Sci USA. 1998;95:3024–3029[Abstract/Free Full Text]
  55. Miller WL, Redfield MM, Burnett JC. Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest. 1989;83:317–320[Web of Science][Medline]
  56. Clarke JG, Benjamin N, Larkin SW. Endothelin is a potent long-lasting vasoconstrictor in man. Am J Physiol. 1989;257:H2033–2035[Web of Science][Medline]
  57. Haynes WG, Clarke JG, Cockcroft JR, Webb DJ. Pharmacology of endothelin-1 in vivo in humans. J Cardiovasc Pharmacol. 1991;17:284–286
  58. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994;344:852–854[CrossRef][Web of Science][Medline]
  59. Haynes WG, Ferro CJ, O'Kane KPJ. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation. 1996;93:1860–1870[Abstract/Free Full Text]
  60. Ishikawa T, Yanagisawa M, Kimura S, Goto K, Masaki T. Positive inotrope action of novel vasoconstrictor peptide endothelin on guinea pig atria. Am J Physiol. 1988;255:H970–973[Web of Science][Medline]
  61. Wagner OF, Vierhapper H, Gasic S, Nowotny P, Waldhausl W. Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation. Eur J Clin Invest. 1992;22:277–282[Web of Science][Medline]
  62. Weitzberg E, Ahlborg G, Lundberg JM. Differences in vascular effects and removal of endothelin-1 in human lung, brain, and skeletal muscle. Clin Physiol. 1993;13:653–662[Web of Science][Medline]
  63. Cowburn PJ, Cleland JGF, McArthur JD. Endothelin-1 has haemodynamic effects at pathophysiological concentrations in patients with left ventricular dysfunction. Cardiovasc Res. 1998;39:563–570[Abstract/Free Full Text]
  64. MacCarthy PA, Grocott-Mason R, Prendegast BD, Shah AM. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart. Circulation. 2000;101:142–147[Abstract/Free Full Text]
  65. Onishi K, Ohno M, Little WC, Cheng C. Endogenous endothelin-1 depresses left ventricular systolic and diastolic performance in congestive heart failure. J Pharmacol Exp Ther. 1999;288:1214–1222[Abstract/Free Full Text]
  66. Kawaguchi H, Sawa H, Yasuda H. Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. J Mol Cell Cardiol. 1990;22:839–842[CrossRef][Web of Science][Medline]
  67. Boarder MR, Marriot DB. Characterization of endothelin-1 stimulation of catecholamine release from adrenal chromaffin cells. J Cardiovasc Pharmacol. 1989;13:2223–2224
  68. Cao L, Banks RO. Cardiorenal actions of endothelin, part 1: effects of converting enzyme inhibition. Life Sci. 1990;46:577–583[CrossRef][Web of Science][Medline]
  69. Emori T, Hirata Y, Ohta K. Cellular mechanisms of endothelin-1 release by angiotensin and vasopressin. Hypertension. 1991;18:165–170[Abstract/Free Full Text]
  70. Barton M, Shaw S, Duscio LV, Moreau P, Luscher TF. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo-role of ETA receptors for endothelin regulation. Biochem Biophys Res Comm. 1997;238:861–865[CrossRef][Web of Science][Medline]
  71. Donckier JE, Massart PE, Hodeige D. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition. Circulation. 1997;96:1250–1256[Abstract/Free Full Text]
  72. Yang Z, Richard V, Von Segesser L. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. Circulation. 1990;82:188–195[Abstract/Free Full Text]
  73. Komuro I, Kurihara H, Sugiyama T. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett. 1988;238:249–252[CrossRef][Web of Science][Medline]
  74. Ito H, Hirata Y, Hiroe M. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circulation Res. 1991;69:209–215[Abstract/Free Full Text]
  75. Peifley KA, Winkles JA. Angiotensin II and endothelin-1 increase fibroblast growth factor-2 mRNA expression in vascular smooth muscle cells. Biochem Biophys Res Comm. 1998;242:202–208[CrossRef][Web of Science][Medline]
  76. Gonon A, Wang QD, Pernow J. The endothelin A receptor antagonist LU 135252 protects the myocardium from neutrophil injury during ischaemia/reperfusion. Cardiovascular Res. 1998;39:674–682[Abstract/Free Full Text]
  77. Garjani A, Wainwright CL, Zeitlin IJ, Wilson C, Slee SJ. Effects of endothelin-1 and the ETAreceptor antagonist, BQ-123, on ischaemic arrhythmias in anaesthetised rats. J Cardiovasc Pharmacol. 1995;25:634–642[Web of Science][Medline]
  78. Sharif I, Kane KA, Wainwright CL. Endothelin and ischaemic arrhythmias-antiarrhythmic or arrhythmogenic. Cardiovascular Res. 1998;39:625–632[Abstract/Free Full Text]
  79. Burrell KM, Molenaar P, Dawson PJ, Kaumann AJ. Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 209670. J Pharmacol Exp Ther. 2000;292:449–459[Abstract/Free Full Text]
  80. Rodeheffer RJ, Lerman A, Heublein DM, Burnett JC Jr. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clinic Proc. 1992;67:719–724[Web of Science][Medline]
  81. Lerman A, Kubo SH, Tschumperlin LK, Burnett JC Jr. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol. 1992;20:849–853[Abstract]
  82. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation. 1992;85:510–517[Abstract/Free Full Text]
  83. Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol. 1994;23:1427–1433[Abstract]
  84. Good JM, Nihoyannopoulos P, Ghatei MA. Elevated plasma endothelin concentrations in heart failure: An effect of angiotensin II? Eur Heart J. 1994;15:1634–1640[Abstract/Free Full Text]
  85. Pacher R, Bergler Klein J, Globits S. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol. 1993;71:1293–1299[CrossRef][Web of Science][Medline]
  86. Tsutamoto T, Hisanaga T, Fukai D. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol. 1995;76:803–808[CrossRef][Web of Science][Medline]
  87. Pacher R, Stanek B, Hulsmann M. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol. 1996;27:633–641[Abstract]
  88. Galatius-Jensen S, Wroblewski H, Emmeluth C. Plasma endothelin in congestive cardiac failure: a predictor of cardiac death? J Cardiac Failure. 1996;2:71–76[CrossRef][Medline]
  89. Kiowski W, Sutsch G, Hunziker P. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995;346:732–736[CrossRef][Web of Science][Medline]
  90. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann Intern Med. 1991;114:464–469[Abstract/Free Full Text]
  91. Dupuis J, Stewart DJ, Cernacek P, Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation. 1996;94:1578–1584[Abstract/Free Full Text]
  92. Dupuis J, Cernacek P, Tardif J-C. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J. 1998;135:614–620[CrossRef][Web of Science][Medline]
  93. Dupuis J, Rouleau J, Cernacek P. Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction. Circulation. 1998;98:1684–1687[Abstract/Free Full Text]
  94. Tsutamoto T, Wada A, Hisanaga T. Relationship between endothelin-1 extraction in the peripheral circulation and systemic vascular resistance in patients with severe congestive heart failure. J Am Coll Cardiol. 1999;33:530–537[Abstract/Free Full Text]
  95. Stangl K, Dschietzig T, Richter C. Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure: acute effects of vasodilator therapy. Circulation. 2000;102:1132–1138[Abstract/Free Full Text]
  96. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Comm. 1994;199:1461–1465[CrossRef][Web of Science][Medline]
  97. Dupuis J, Goresky CA, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: Exclusive role of ET(B) receptors. J Appl Physiol. 1996;81:1510–1515[Abstract/Free Full Text]
  98. Cowburn PJ, Cleland JGF, McDonagh TA. Endothelin clearance in patients with chronic heart failure: implications for anti-endothelin therapy. Circulation. 1998;98:I-3
  99. Kobayashi T, Miyauchi T, Sakai S. Down-regulation of ETB receptor, but not ETA receptor, in congestive lung secondary to heart failure. Are marked increases in circulating endothelin-1 partly attributable to decreases in lung ETB receptor-mediated clearance of endothelin-1? Life Sci. 1997;62:185–193[CrossRef]
  100. Clozel M, Breu V, Burri K. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993;365:759–761[CrossRef][Medline]
  101. Sakai S, Miyauchi T, Kobayashi M. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 1996;384:353–355[CrossRef][Medline]
  102. Sakai S, Miyauchi T, Sakurai T. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. J Am Coll Cardiol. 1996;28:1580–1588[Abstract]
  103. Fraccarollo D, Hu K, Galuppo P, Gaudron P, Ertl G. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction. Possible involvement of myocardial endothelin system in ventricular remodeling. Circulation. 1997;96:3963–3973[Abstract/Free Full Text]
  104. Mulder P, Richard V, Derumeaux G. Role of endogenous endothelin in chronic heart failure. Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997;96:1976–1982[Abstract/Free Full Text]
  105. Spinale FG, Walker JD, Mukherjee R. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Circulation. 1997;95:1918–1929[Abstract/Free Full Text]
  106. Borgeson DD, Grantham JA, Williamson EE. Chronic oral endothelin type A receptor antagonism in experimental heart failure. Hypertension. 1998;31:766–770[Abstract/Free Full Text]
  107. Mulder P, Richard V, Bouchart F. Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure. Cardiovasc Res. 1998;39:600–608[Abstract/Free Full Text]
  108. Saad D, Mukherjee R, Thomas PB. The effects of endothelin-A receptor blockade during the progression of pacing-induced congestive heart failure. J Am Coll Cardiol. 1998;32:1779–1786[Abstract/Free Full Text]
  109. Nguyen QT, Cernacek P, Calderoni A. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation. 1998;98:2323–2330[Abstract/Free Full Text]
  110. Mishima T, Tanimura M, Suzuki G. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation. 2000;35:222–229
  111. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med. 1998;338:784–790[Abstract/Free Full Text]
  112. Wenzel RR, Fleisch M, Shaw S. Haemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation. 1998;98:2235–2240[Abstract/Free Full Text]
  113. Kyriakides ZS, Kremastinos DT, Kolettis TM. Acute endothelin-A receptor antagonism prevents normal reduction of myocardial ischemia on repeated balloon inflations during angioplasty. Circulation. 2000;102:1937–1943[Abstract/Free Full Text]
  114. Williamson DJ, Wallman LL, Jones R. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation. 2000;102:411–418[Abstract/Free Full Text]
  115. Sutsch G, Kiowski W, Yan X. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe heart failure. Circulation. 1998;98:2262–2268[Abstract/Free Full Text]
  116. Packer M, Caspi A, Charlon V. Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure—results of the REACH-1 trial. Circulation. 1998;98:I-3
  117. Krum H, Charlon V, Widmann T, Packer M. Long-term, open-label experience with an endothelin receptor antagonist, bosentan, in patients with severe chronic heart failure. Circulation. 1999;100:I-646–7
  118. Love MP, Haynes WG, Gray GA, Webb DJ, McMurray JJV. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ET(A) receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation. 1996;94:2131–2137[Abstract/Free Full Text]
  119. Cowburn PJ, Cleland JGF, McArthur JD. Short-term haemodynamic effects of BQ-123, a selective endothelin ETA-receptor antagonist, in chronic heart failure. Lancet. 1998;352:201–202[Web of Science][Medline]
  120. Givertz MM, Colucci WS, LeJemtel TH. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation. 2000;101:2922–2927[Abstract/Free Full Text]
  121. Spieker LE, Mitrovic V, Noll G. Acute hemodynamic and neurohumoral effects of selective ETAreceptor blockade in patients with congestive heart failure. J Am Coll Cardiol. 2000;35:1745–1752[Abstract/Free Full Text]
  122. Cowburn PJ, Cleland JGF, McArthur JD. EndothelinBreceptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 1999;33:932–938[Abstract/Free Full Text]
  123. Verhaar MC, Strachan FE, Newby DE. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation. 1998;97:752–756[Abstract/Free Full Text]
  124. Love MP, Ferro CJ, Haynes WG, Webb DJ, McMurray JJV. Selective or non-selective endothelin receptor blockade in chronic heart failure? Circulation. 1996;94:I-74
  125. Cowburn PJ, Cleland JGF, McDonagh TA. Adverse hemodynamic effects of a selective endothelin ETBreceptor antagonist in patients with chronic heart failure: reversal with a selective endothelin ETAreceptor antagonist. Circulation. 1998;98:I-718
  126. Strachan FE, Spratt JC, Wilkinson IB. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension. 1999;33:581–585[Abstract/Free Full Text]
  127. Lancet. 1990;336:1–6[CrossRef][Web of Science][Medline]
  128. Packer M, Carver JR, Rodeheffer RJ. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468–1475[Abstract]
  129. Lancet. 1993;341:1146[Web of Science][Medline]
  130. Califf RM, Adams KF, McKenna WJ. A randomised controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomised Survival Trial (FIRST). Am Heart J. 1997;134:44–54[CrossRef][Web of Science][Medline]
  131. Wada A, Tsutamoto T, Fukai D. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. J Am Coll Cardiol. 1997;30:1385–1392[Abstract]
  132. Ohnishi M, Wada A, Tsutamoto T, Fukai D, Kinoshita M. Comparison of the acute effects of a selective ETAand a mixed ETA/ETBreceptor antagonist in heart failure. Cardiovasc Res. 1998;39:617–624[Abstract/Free Full Text]
  133. Sutsch G, Bertel O, Rickenbacher P. Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. Am J Cardiol. 2000;85:973–976[CrossRef][Web of Science][Medline]
  134. Schmetterer L, Dallinger S, Bobr B. Systemic and renal effects of an ETAreceptor subtype-specific antagonist in healthy subjects. Br J Pharmacol. 1998;124:930–934[CrossRef][Web of Science][Medline]
  135. King-Van Vlack CE, Mewburn JD, Chapler CK. Receptor-mediated vascular and metabolic actions of endothelin-1 in canine small intestine. Am J Physiol. 1999;276:G1131–1136[Medline]
  136. Ahn K, Sisneros AM, Herman SB. Novel selective quinazoline inhibitors of endothelin converting enzyme-1. Biochem Biophys Res Comm. 1998;243:184–190[CrossRef][Web of Science][Medline]
  137. Wada A, Tsutamoto T, Ohnishi M. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohormonal functions in congestive heart failure. Comparison of effects with those of endothelin A receptor antagonism. Circulation. 1999;99:570–577[Abstract/Free Full Text]
  138. Mylona P, Cleland JGF. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Eur J Heart Failure. 1999;1:197–200[CrossRef][Web of Science][Medline]
  139. Sutsch G, Bertel O, Kiowski W. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drugs Ther. 1996;10:717–725[CrossRef][Web of Science]
  140. Chen HH, Salz L, McKinley LJ. Safety and efficacy of an orally active selective endothelin ETA receptor antagonist in moderate-severe human chronic heart failure. Eur J Heart Failure. 1999;1:76
  141. Torre-Amione G, Durand J, Bozkurt B. Results of a randomized, placebo-controlled, hemodynamic trial with an intravenous endothelin-1 receptor antagonist in patients with congestive heart failure. Circulation. 1999;100:I-647

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ESC Textbook of Cardiovascular MedicineHome page
J. McMurray, M. Petrie, K. Swedberg, M. Komajda, S. Anker, and R. Gardner
CHAPTER 23 Heart Failure
ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
N F Kelland and D J Webb
Clinical trials of endothelin antagonists in heart failure: publication is good for the public health
Heart, January 1, 2007; 93(1): 2 - 4.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
N. F. Kelland and D. J. Webb
Clinical Trials of Endothelin Antagonists in Heart Failure: A Question of Dose?
Experimental Biology and Medicine, June 1, 2006; 231(6): 696 - 699.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
S J Leslie, J C S Spratt, S P McKee, F E Strachan, D E Newby, D B Northridge, M A Denvir, and D J Webb
Direct comparison of selective endothelin A and non-selective endothelin A/B receptor blockade in chronic heart failure
Heart, July 1, 2005; 91(7): 914 - 919.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
P. J. Cowburn, J. G.F. Cleland, T. A. McDonagh, J. D. McArthur, H. J. Dargie, and J. J. Morton
Comparison of selective ETA and ETB receptor antagonists in patients with chronic heart failure
Eur J Heart Fail, January 1, 2005; 7(1): 37 - 42.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
R.A de Boer and D.J van Veldhuisen
Polypharmacy in chronic heart failure: practical issues regarding the use of angiotensin-converting enzyme inhibitors, beta-blockers and other drugs
Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D111 - D116.
[Abstract] [PDF]

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cowburn, P.J.
Right arrow Articles by Cleland, J.G.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cowburn, P.J.
Right arrow Articles by Cleland, J.G.F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?